Cancer-associated venous thromboembolism in the direct oral anticoagulants era: Insight from the COMMAND VTE Registry-2

• Published in: Thrombosis research Vol. 234; pp. 86 - 93
• Main Authors: Chatani, Ryuki, Yamashita, Yugo, Morimoto, Takeshi, Mushiake, Kazunori, Kadota, Kazushige, Kaneda, Kazuhisa, Nishimoto, Yuji, Ikeda, Nobutaka, Kobayashi, Yohei, Ikeda, Satoshi, Kim, Kitae, Inoko, Moriaki, Takase, Toru, Tsuji, Shuhei, Oi, Maki, Takada, Takuma, Otsui, Kazunori, Sakamoto, Jiro, Ogihara, Yoshito, Inoue, Takeshi, Usami, Shunsuke, Chen, Po-Min, Togi, Kiyonori, Koitabashi, Norimichi, Hiramori, Seiichi, Doi, Kosuke, Mabuchi, Hiroshi, Tsuyuki, Yoshiaki, Murata, Koichiro, Takabayashi, Kensuke, Nakai, Hisato, Sueta, Daisuke, Shioyama, Wataru, Dohke, Tomohiro, Nishikawa, Ryusuke, Kimura, Takeshi
• Format: Journal Article
• Language: English
• Published: United States 01.02.2024
• Subjects: Recurrence; Mortality; Cardio-oncology; Anticoagulant; Bleeding; Cancer-associated thrombosis; Venous thromboembolism
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2023.12.016

There is a paucity of data on real-world management strategies and clinical outcomes of cancer-associated venous thromboembolism (VTE) in the direct oral anticoagulants (DOACs) era. To investigate the status of cancer-associated VTE in the DOAC era. This multicenter, retrospective cohort study among 31 centers in Japan between 2015 and 2020 enrolled 5197 consecutive patients with acute symptomatic VTE, who were divided into 1507 patients (29 %) with active cancer and 3690 patients (71 %) without. The cumulative 3-year rate of anticoagulation discontinuation was significantly higher in patients with active cancer than in those without (62.7 % vs. 59.1 %, P < 0.001). The cumulative 5-year incidence of recurrent VTE was higher in patients with active cancer than in those without (10.1 % vs. 9.1 %, P = 0.01), however, after adjusting for the confounders and competing risk of mortality, the excess risk of the active cancer group relative to the no active cancer group was no longer significant (HR: 0.95, 95 % CI: 0.73-1.24). The cumulative 5-year incidence of major bleeding was much higher in the active cancer group (20.4 % vs. 11.6 %, P < 0.001). Even after adjusting for the confounders and competing risk of mortality, the risk of the active cancer group relative to the no active cancer group remained significant (HR: 1.36, 95 % CI: 1.11-1.66). The current large real-world registry revealed that the risk of major bleeding was still higher in patients with active cancer than in those without, leading to the frequent anticoagulation discontinuation, which has been still a huge challenge to overcome in the DOAC era.